LeMaitre Vascular, Inc. (NASDAQ:LMAT) Receives $105.80 Average Price Target from Analysts

LeMaitre Vascular, Inc. (NASDAQ:LMAT) has been assigned a consensus rating of “Hold” from the seven brokerages that are covering the stock, Marketbeat reports. Four investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $105.80.

Several analysts have issued reports on LMAT shares. Zacks Research cut LeMaitre Vascular from a “strong-buy” rating to a “hold” rating in a report on Thursday, January 1st. Wall Street Zen upgraded LeMaitre Vascular from a “hold” rating to a “buy” rating in a report on Saturday, February 21st. Wells Fargo & Company boosted their price target on shares of LeMaitre Vascular from $87.00 to $94.00 and gave the company an “equal weight” rating in a research report on Thursday, February 26th. Citizens Jmp upped their price objective on shares of LeMaitre Vascular from $113.00 to $118.00 and gave the company a “market outperform” rating in a report on Thursday, February 26th. Finally, Barrington Research lifted their target price on shares of LeMaitre Vascular from $95.00 to $105.00 and gave the stock an “outperform” rating in a research note on Thursday, February 26th.

LeMaitre Vascular Stock Down 0.8%

LMAT stock opened at $109.20 on Wednesday. The company has a market cap of $2.49 billion, a price-to-earnings ratio of 43.51, a PEG ratio of 3.17 and a beta of 0.66. The company has a current ratio of 12.89, a quick ratio of 10.95 and a debt-to-equity ratio of 0.43. LeMaitre Vascular has a 12 month low of $71.42 and a 12 month high of $115.33. The firm has a 50-day moving average of $90.36 and a two-hundred day moving average of $88.87.

LeMaitre Vascular (NASDAQ:LMAT) last issued its earnings results on Wednesday, February 25th. The medical instruments supplier reported $0.68 earnings per share for the quarter, topping the consensus estimate of $0.67 by $0.01. The business had revenue of $64.45 million for the quarter, compared to analysts’ expectations of $62.98 million. LeMaitre Vascular had a return on equity of 14.72% and a net margin of 23.13%.The business’s revenue for the quarter was up 15.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.49 EPS. LeMaitre Vascular has set its FY 2026 guidance at 2.810-3.010 EPS and its Q1 2026 guidance at 0.640-0.690 EPS. As a group, analysts forecast that LeMaitre Vascular will post 1.94 earnings per share for the current fiscal year.

LeMaitre Vascular Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, March 26th. Stockholders of record on Thursday, March 12th will be issued a dividend of $0.25 per share. The ex-dividend date is Thursday, March 12th. This represents a $1.00 dividend on an annualized basis and a dividend yield of 0.9%. This is an increase from LeMaitre Vascular’s previous quarterly dividend of $0.20. LeMaitre Vascular’s payout ratio is 31.87%.

Insider Activity

In related news, insider Trent G. Kamke sold 1,044 shares of the stock in a transaction that occurred on Friday, February 27th. The stock was sold at an average price of $110.29, for a total value of $115,142.76. Following the completion of the transaction, the insider directly owned 6,677 shares in the company, valued at approximately $736,406.33. This represents a 13.52% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director David B. Roberts sold 8,464 shares of the firm’s stock in a transaction on Friday, February 27th. The stock was sold at an average price of $106.80, for a total value of $903,955.20. Following the sale, the director directly owned 17,979 shares of the company’s stock, valued at approximately $1,920,157.20. This trade represents a 32.01% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 215,438 shares of company stock valued at $23,062,911. 9.50% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On LeMaitre Vascular

Large investors have recently modified their holdings of the business. Parkside Financial Bank & Trust grew its holdings in shares of LeMaitre Vascular by 1,913.3% during the 2nd quarter. Parkside Financial Bank & Trust now owns 302 shares of the medical instruments supplier’s stock worth $25,000 after purchasing an additional 287 shares during the period. Cornerstone Planning Group LLC lifted its position in LeMaitre Vascular by 534.0% in the third quarter. Cornerstone Planning Group LLC now owns 336 shares of the medical instruments supplier’s stock valued at $30,000 after buying an additional 283 shares during the last quarter. MAI Capital Management acquired a new position in LeMaitre Vascular in the third quarter valued at about $38,000. First Horizon Corp purchased a new position in LeMaitre Vascular during the third quarter worth about $39,000. Finally, Geneos Wealth Management Inc. increased its position in shares of LeMaitre Vascular by 250.3% during the first quarter. Geneos Wealth Management Inc. now owns 557 shares of the medical instruments supplier’s stock valued at $47,000 after acquiring an additional 398 shares during the last quarter. Institutional investors and hedge funds own 84.64% of the company’s stock.

About LeMaitre Vascular

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.